A once-daily pill taken alongside chemotherapy left tumors undetectable on scans in about one in 12 patients with advanced pancreatic cancer, according to early trial results reported by the BBC, LBC and Cambridge News. Researchers say the findings are promising but small, and they stress the result is not a cure.
The drug, daraxonrasib, targets a mutated gene that drives most pancreatic tumors. The results were presented at a cancer research meeting in Barcelona.
The median follow-up was 18 months. Fewer than 5% of participants stopped treatment, which is regarded as low, Cambridge News reported.
Daraxonrasib is a KRAS inhibitor. It locks onto a mutated version of the KRAS gene, found in more than nine in 10 pancreatic tumors, which sends constant signals telling cancer cells to grow. Shutting that signal off can stop tumors from spreading, the reports say. The BBC reported that the drug has already been approved in the U.S. Cambridge News said it made global headlines in May after a study found it nearly doubled survival time compared with chemotherapy alone in aggressive, advanced disease.
Because similar mutations appear in dozens of other cancers, including lung and ovarian, the BBC reported that the drug might eventually help many more patients. Cancer Research UK's Dr. Sam Godfrey said he hopes early success in pancreatic cancer can be extended to other cancers.
Dr. Wungki Park, an oncologist at Memorial Sloan Kettering Cancer Center in New York who presented the findings, told the Press Association it was “a massive, massive breakthrough.” Asked whether patients whose tumors vanished from scans were considered cured, he said it was “the closest to cure.” He added that longer-term survival data will come as the trial continues, and that cancer often develops resistance to drugs, which the combination aims to delay as long as possible.
Others urged caution. Pancreatic Cancer UK's Dr. Madina Kara called the study small and at an early stage, though encouraging. Cancer Research UK chief executive Michelle Mitchell described the results as the biggest leap forward in decades for pancreatic cancer patients, but said survival remains very low and more trials are needed. The BBC noted that doctors cannot yet say how long the disease might be held at bay.
Pancreatic cancer is among the deadliest and hardest to treat. Chemotherapy can shrink tumors a little, but the disease often grows back, and most patients with advanced disease survive months rather than years, the BBC reported. In the United States, it accounts for about 3% of all cancers and about 8% of cancer deaths, killing around 53,000 people a year, according to the BBC. In Britain, Cancer Research UK counts 11,500 diagnoses and around 10,200 deaths a year.
For patients and families, the findings suggest the pill-plus-chemotherapy combination may offer more time and, in some cases, deeper responses than chemotherapy alone. Because the trial was small and early, it cannot yet show that.
A phase three trial in the U.S. already has enough patients, Park said, though some European sites may still have space, Cambridge News reported. Experts say the combination must be tested in a larger trial before it can be assessed for use on Britain's National Health Service. Pancreatic Cancer UK called on the U.K. government to increase investment in research and clinical trials.
Around Prague, based on reporting by BBC, LBC, Cambridge News